Discounted Cash Flow (DCF) Analysis Levered

BlackRock Health Sciences Trust (BME)

$39.565

+0.29 (+0.75%)
All numbers are in Millions, Currency in USD
Stock DCF: -61.71 | 39.565 | overvalue

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 60.7322.8980.2980.0959.6683.93118.08166.12233.70328.77
Revenue (%)
Operating Cash Flow -1.172.05-14.10-19.35-21.56-11.89-16.73-23.53-33.10-46.57
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ------11.89-16.73-23.53-33.10-46.57

Weighted Average Cost Of Capital

Share price $ 39.565
Beta 0.747
Diluted Shares Outstanding 11.58
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 7.424
Total Debt -
Total Equity 458.20
Total Capital 458.20
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 60.7322.8980.2980.0959.6683.93118.08166.12233.70328.77
Operating Cash Flow -1.172.05-14.10-19.35-21.56-11.89-16.73-23.53-33.10-46.57
Capital Expenditure ----------
Free Cash Flow ------11.89-16.73-23.53-33.10-46.57
WACC
PV LFCF -10.30-13.49-17.67-23.14-30.31
SUM PV LFCF -101.96

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 7.42
Free cash flow (t + 1) -47.50
Terminal Value -876.39
Present Value of Terminal Value -612.73

Intrinsic Value

Enterprise Value -714.70
Net Debt -0
Equity Value -714.70
Shares Outstanding 11.58
Equity Value Per Share -61.71